ClinicalTrials.gg
CompletedNCT04981431Updated Mar 29, 2022

A Study to Learn How Safe Elinzanetant is, How it Affects the Body, and How it Moves Into, Through and Out of the Body After Single and Multiple Doses in Japanese Healthy Female Adults

A Phase 1 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, sponsored by Bayer. Completed at 1 site in Japan. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-29.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

Researchers are looking for a new way to treat women who have symptoms that are caused by the sex hormonal changes that happen when a woman's body is going through the menopause. These symptoms include Vasomotor Symptoms (VMS) (hot flashes), and changes in blood pressure. Menopause is when women stop having a menstrual cycle, also called a period. During the period, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life.

In this study, researchers want to learn more about a new substance called elinzanetant. Elinzanetant was developed to treat symptoms caused by sex hormonal changes. It works by blocking a group of proteins called neurokinins from sending signals to other parts of the body, which play a role in starting the symptoms.

In this study, the researchers will learn how safe elinzanetant is and how it affects the body of healthy Japanese women compared to a placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it. Before a new treatment can be given to patients, researchers do studies in healthy participants to learn more about its safety and how it acts in the body.

There will be 2 parts to this study. In Part A, the participants will take a single dose of either elinzanetant or the placebo. In Part B, the participants will take multiple doses of elinzanetant or the placebo. The participants will take each study treatment as capsules by mouth.

The main purpose of this study is to learn how safe elinzanetant is and how it affects the body. To answer this question, the researchers will collect the medical problems the participants have after receiving the treatment and that may or may not be related to the study treatment. These medical problems are also known as "adverse events".

During Part A, the participants will stay at their study site for a total of 9 days. They will take either elinzanetant or the placebo only on Day 1 of their stay. During Part B, the participants will stay at their study site for a total of 15 days. They will take either elinzanetant or the placebo once a day for 7 days of their stay. Each participant will be in the study for a total of approximately 5 weeks for Part A and approximately 6 weeks for Part B.

During the study, the doctors will:

  • take blood and urine samples;
  • check the participants' health;
  • ask the participants questions about what medicines they are taking and if they are having adverse events.
02

Conditions studied

  • Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, blood pressure, pulse rate, 12 lead (ECG), body temperature, and laboratory tests.
  • Non-smoker, at least from 3 months before the screening visit onwards.
  • Body weight of at least 40 kg and (BMI) within the range 18.0 and 30.0 kg/m\^2 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Any abnormal findings in medical history and physical examination.
  • History or evidence of any clinically relevant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other clinically relevant disease.
  • Relevant diseases or febrile illness within the last 4 weeks prior to the first study intervention administration.
  • Regular use of medicines, or dietary supplements or other substances, e.g., carnitine products, anabolics, high dose vitamins.
  • Use of any systemic or topical medicine or substance within 4 weeks before first study drug intervention, which oppose the study objectives, or which might influence them. This includes medicines and natural remedies (e.g St. John's wort) that are altering the activity of enzyme and the transporters Breast Cancer Resistance Protein (BCRP) and P-gp.
  • : PR interval > 210 msec, corrected using Bazett's formula (QTcB) >450 msec, QRS duration > 110 msec at screening visit.
  • Systolic blood pressure below 90 or above 140 mmHg; diastolic blood pressure below 40 or above 90 mmHg at screening visit.
  • Pulse rate below 50 or above 90 beats per minute (bpm; a lower pulse rate between 45 and 50 bpm is acceptable in case of normal thyroid function and absence of symptoms of bradycardia) at screening visit.
  • Participants with a presence of any of the following, confirmed by a repeat test: (AST), alanine aminotransferase (ALT) and/or above 1.2 x (ULN) at screening visit.
  • Participants with a presence of gamma-glutamyl transferase (GGT) > ULN confirmed by a repeat test, CK (creatine kinase)>2x ULN, and thyroid-stimulating hormone (TSH) outside normal range at screening visit.
  • History of COVID-19 (coronavirus disease 2019).
  • Suspected or confirmed active or prior SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) infection according to local guidelines/practice.
  • Contact with SARS-CoV-2- positive or COVID-19 patient within the last 4 weeks prior to admission to the study site.
  • Positive SARS-CoV-2 viral RNA (ribonucleic acid) test.
  • Vaccination against SARS-CoV-2 within 14 days before first administration of the study intervention or vaccination planned before completion of the last study visit.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Elinzanetant single dose step 1

    Each participant will receive a single oral dose of elinzanetant or placebo.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

  • Experimental
    Elinzanetant single dose step 2

    Each participant will receive a single oral dose of elinzanetant or placebo.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

  • Experimental
    Elinzanetant single dose step 3

    Each participant will receive a single oral dose of elinzanetant or placebo.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

  • Experimental
    Elinzanetant single dose step 4

    Each participant will receive a single oral dose of elinzanetant or placebo.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

  • Experimental
    Elinzanetant single dose step 6

    Each participant will receive a single oral dose of elinzanetant or placebo.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

  • Experimental
    Elinzanetant multiple dose step 5

    Each participant will receive multiple doses of elinzanetant or placebo administered once a day for 7 consecutive days.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with and severity of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 weeks after start of dosing

Secondary outcomes

  1. Cmax (maximum observed drug concentration after single dose administration) of elinzanetant

    Only for single dose steps 1 to 4 and 6

    Time frame: Day 1 pre-dose until 144 hours post-dose

  2. Cmax/D (Cmax divided by dose) of elinzanetant

    Only for single dose steps 1 to 4 and 6

    Time frame: Day 1 pre-dose until 144 hours post-dose

  3. AUC (area under the concentration vs. time curve from zero to infinity after single dose) of elinzanetant

    Only for single dose steps 1 to 4 and 6

    Time frame: Day 1 pre-dose until 144 hours post-dose

  4. AUC/D (AUC divided by dose) of elinzanetant

    Only for single dose steps 1 to 4 and 6

    Time frame: Day 1 pre-dose until 144 hours post-dose

  5. Cmax,md (maximum observed drug concentration after multiple dose administration) of elinzanetant

    Only for multiple dose step 5

    Time frame: Day 7 (pre-dose until 144 hours post-dose)

  6. Cmax,md/D (Cmax,md divided by dose) of elinzanetant

    Only for multiple dose step 5

    Time frame: Day 7 (pre-dose until 144 hours post-dose)

  7. AUC(0-24)md (AUC from time 0 to 24 h after multiple dose) of elinzanetant

    Only for multiple dose step 5

    Time frame: Day 7 (pre-dose until 24 hours post-dose)

  8. AUC(0-24)md/D (AUC(0-24)md divided by dose) of elinzanetant

    Only for multiple dose step 5

    Time frame: Day 7 (pre-dose until 24 hours post-dose)

07

Study locations

1 site
  • SOUSEIKAI Fukuoka Mirai Hospital
    Fukuoka, 813-0017, Japan
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Mar 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2021
First posted
Jul 29, 2021
StartActual
Aug 11, 2021
Primary completionActual
Mar 13, 2022
CompletionActual
Mar 13, 2022
Last update
Mar 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04981431
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 29, 2021
Start date
Aug 11, 2021
Primary completion
Mar 13, 2022
Completion
Mar 13, 2022
Last update
Mar 29, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion